Hims · Individual product review
Hims Tadalafil review
Hims Tadalafil: the prescribed schedule within one ingredient offering, with formulation, cost, evidence and availability examined to monitor the offer, the evidence and the plan after prescribing.
The ED Watch editorial desk · Published October 7, 2026 · Updated October 7, 2026
AI-assisted public-document research · Not medically reviewed · No firsthand product testing
We may earn a commission through commercial links. This review does not award a clinical rating. Read the disclosure.
Hims Tadalafil deserves a review separate from the Hims service because it identifies generic tadalafil tablets with daily or as-needed prescribing pathways. The relevant questions concern this preparation's evidence, complete cost and follow-up, not a single score for everything the company sells. This product watch records what the current public material can establish and what still needs confirmation.
The exact product
The feature to watch is the prescribed schedule within one ingredient offering. Match the full ingredient list and dosage form to the prescription actually offered. A company may market conventional tablets, daily products and compounds simultaneously. A service review can describe access or billing while leaving the differences between those medicines unresolved. The identity record below is therefore the starting point for interpreting every price or clinical claim on this page.
| Provider | Hims |
|---|---|
| Listed active ingredients | Generic tadalafil |
| Dosage form | Conventional prescription tablet |
| Regulatory distinction | Conventional tablet listing; verify the actual dispensed product and manufacturer. |
| Source basis | Hims: generic tadalafil tablets · Hims: current ED treatment catalog |
Price, supply and payment
The public cost entry is From $24/month in the current catalog. Watch the payment interval and supplied quantity as closely as the headline. An introductory amount, an approximate article example and a complete renewal quote have different evidentiary value. Do not combine a unit figure from one plan with a monthly banner from another. Save the selected order terms so that a later refill or treatment change can be checked against them.
| Catalog starting figure | From $24/month |
|---|---|
| Potential schedules | Daily and as needed are clinical choices |
| Distinct alternatives | Tadalafil Chews and Daily Hard Mints have separate reviews |
| Price boundary | Starting monthly language does not confirm the amount due now |
What the research can support
The research relevant to the offer concerns approved tadalafil tablet evidence; longer persistence does not select the schedule. It leaves selected strength, count and billing period unverified. That boundary prevents ingredient studies or provider satisfaction surveys from turning into finished-product efficacy scores. Ask whether a quoted timing or performance result measured the exact preparation and a clinically relevant outcome. A useful review can recognize an evidence gap without asserting that an unstudied product must be ineffective.
| Evidence boundary | approved tadalafil tablet evidence; longer persistence does not select the schedule |
|---|---|
| Not established here | selected strength, count and billing period |
| Clinical and regulatory references | MedlinePlus: Tadalafil · FDA: Compounding and the FDA — questions and answers · DailyMed: Tadalafil prescribing information, including section 5.11 · MedlinePlus: Sildenafil |
Safety questions for the prescriber
Monitoring starts with accurate prescribing information. Disclose nitrates or recreational nitrites, riociguat, other ED medicines, blood-pressure treatment and relevant heart, kidney, liver or eye history. Do not add Hims Tadalafil to an existing regimen without individualized instructions. The ingredient-specific consideration below should be addressed before a treatment change, not discovered only after an automatic refill has created overlapping supplies.
| One active does not mean no interactions | Nitrates/nitrites, riociguat and other medications require assessment even after previous ED treatment. |
|---|
Availability and the actual prescription
The current availability finding is Public product listing; individual eligibility and current prescription require confirmation. Treat this as a dated documentary observation. Account eligibility and product catalogs can change, while public safety pages may remain accessible. Confirm the actual offered medicine, quantity and pharmacy instructions when enrolling or switching. A reachable page is not evidence that a new prescription or new-customer plan has been approved.
Refills, changes and cancellation
The next step to watch is the response review. Record whether the original concern improved, what unwanted effects occurred and whether the instructions were followed. Ask the clinician “Which schedule is intended and what follow-up will determine whether it suits me?” Then confirm any treatment change in the next shipment and billing record. Administrative cancellation and clinical stopping instructions are separate states; one should not be inferred from the other.
| Next charge | The next order date is the charge/processing date; a first refill can be scheduled early. |
|---|---|
| Cancellation notice | At least 48 hours before the next order, according to support guidance. |
| Already processing | Ending a subscription does not cancel an order already processing or shipped. |
| Refund boundary | No refund guaranteed after pharmacy processing. |
| Policy sources | Hims Support: canceling a subscription · Hims Support: refund policy · Hims Support: when billing occurs |
Compare named products
Use the linked alternatives to examine a concrete change in ingredient, form, schedule or commitment. They are not ordered by clinical superiority. A provider's customer-service features cannot establish the efficacy of a medicine, and a medicine's established evidence cannot verify one provider's delivery or prescribing quality. Keep those judgments separate when deciding what to investigate next.
Questions to keep with the offer
This watch is based on public-source research, with no medical reviewer and no firsthand trial of Hims Tadalafil. We have not tested the checkout, medicine, support response or refund process. The cited records explain the advertised offer and evidence limits. Personal suitability, a complete accepted quote and a workable monitoring plan still require the responsible clinical and service teams.
| Ask about this formula | Which schedule is intended and what follow-up will determine whether it suits me? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Original sources
Provider pages document an advertised offer. Regulatory records and studies address different questions; an ingredient study does not establish a finished compounded product's outcomes.
- Hims: generic tadalafil tabletsProvider product page; daily and as-needed tablet options · Checked 2026-10-07
- Hims: current ED treatment catalogProvider catalog; individual named offers and starting prices · Checked 2026-10-07
- Hims Support: canceling a subscriptionProvider policy; 48-hour notice and orders already processing · Checked 2026-10-07
- Hims Support: refund policyProvider policy; no guaranteed refund after pharmacy processing · Checked 2026-10-07
- Hims Support: when billing occursProvider policy; next order date, charge timing, and subscription intervals · Checked 2026-10-07
- Hims Support: changing the next order dateProvider support; refill rescheduling differs from cancellation · Checked 2026-10-07
- MedlinePlus: TadalafilDrug information; standard tadalafil products · Checked 2026-10-07
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications · Checked 2026-10-07
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination · Checked 2026-10-07
- MedlinePlus: SildenafilDrug information; standard sildenafil products · Checked 2026-10-07